At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Illumina的外部链接
BaseSpace Clarity LIMS is a laboratory information management system that helps genomics labs track samples and manage workflows for an optimized and efficient lab.
Illumina转发了
After an incredible week at the 2025 AGBT - Advances in Genome Biology and Technology Conference, Niall J Lennon and I reflected on how Illumina and Broad Clinical Labs are advancing multiomics to unlock secrets of biology for better health. Together, we’re helping illuminate the parts of biology that have been so elusive, getting closer to cracking the code – literally – that lives in each of us, and using it to help us all live healthier, longer lives.
Today, we recognize the 300 million people worldwide living with a rare disease—and the countless others impacted, from families to healthcare professionals. #RareDiseaseDay is more than awareness; it’s a call to action. Through the Rare Barometer program, EURORDIS-Rare Diseases Europe collects patient survey data to help push for better diagnostics, care, and policies. These surveys don’t just gather numbers—they amplify real voices, shaping the future of rare disease advocacy. See how patient insights are driving real change: https://bit.ly/4ihouAm
Multiomics took center stage at #AGBT25! We shared the next wave of omics technologies that will unlock a new level of biological insights to accelerate precision health. The future is now. Special thank you to our customers, partners, and all attendees who joined us to explore our latest solutions. This is just the beginning. Dive into our innovation roadmap here: https://bit.ly/3D7d2IM.
Medical analyst Graysen Vigneux, PhD said Illumina’s new spatial technology offers "unprecedented resolution and scalability. By integrating high-throughput sequencing with spatial analysis, Illumina is setting a new standard in scientific research.” Medical Device Network has the story: https://bit.ly/3XmUZVJ #AGBT25
Yesterday at our AGBT Gold Sponsor Workshop, customers joined us on stage to share early data and insights from one of our latest innovations: Illumina spatial technology. They shared how the differentiated scale and resolution of this technology is already driving new insights: "Our early analyses with this technology identified and localized molecular dysregulation associated with active epithelial cell remodeling in pulmonary fibrosis. We believe this will aid in identifying therapeutic targets which can be used to stop or slow the progression of disease."?-?Nicholas Banovich, PhD, at TGen - Part of City of Hope "With this new technology we were able to profile millions of cells on just two substrates and found biomarkers that are not included in targeted approaches." -?Jasmine Plummer, PhD, at St. Jude Children's Research Hospital "Large-scale and unbiased whole-transcriptome capture are the ideal components of a discovery platform capable of finding novel marker genes and simultaneously validating them across multiple tissue sections within a single experiment."?-?Michal Lipinski, PhD, at the Broad Institute of MIT and Harvard Missed the Gold Sponsor workshop? Register here to get the recording: https://bit.ly/3X4o4Ft
At #AGBT25, we presented our single-cell CRISPR solution—a high-throughput method for interrogating the gene expression of individual cells. Now, researchers can uncover insights faster at an unprecedented scale. A game-changer for understanding genotype-phenotype interactions. We're here at AGBT—stop by and see us! More on single-cell CRISPR: https://bit.ly/3QFq3w1
"What we're doing now will change how we look at preventive care, diagnosis, and treatment." —Jacob Thaysen, PhD, CEO of Illumina. At our Gold Sponsor workshop today at #AGBT25, Jacob took the stage to share how multiomics is unlocking a deeper understanding of biology—one that goes beyond the genome to reveal the full picture of health and disease. From scaling spatial to accelerating single-cell research, we’re making these breakthroughs more accessible, more powerful, and more connected than ever before. The next frontier is here, and we’re building it together. https://bit.ly/3D7d2IM
Peek into the future of discovery with spatial transcriptomics at an unprecedented scale. https://bit.ly/3D7d2IM
Five?disruptive technologies. One transformative vision for multiomics. Get an exclusive first look at what's next for precision medicine at #AGBT25. Join us at our Gold Sponsor Workshop: February 24 | 12-1:30 PM?ET. Learn more: https://bit.ly/3Xgi8JD.
Coming to you live from #AGBT25—we are excited to share new omics solutions to bring quality, scale, accuracy, and replicability to multiomics research. Attend our Gold Sponsor workshop tomorrow at 12 PM ET, where we will be joined by our customers to share early access data and insights about our robust innovation roadmap. While you're here, make sure not to miss: ?Mainstage presentations ?Poster presentations ?Demos in our lounge, Osprey – 1 ?+ more Get the details on our AGBT presentations, and register to receive a replay: https://bit.ly/3X4o4Ft